Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bitcoin ETF (BITU) vs GSK plc (GSK) Price & Performance

ProShares Ultra Bitcoin ETFTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bitcoin ETF vs GSK plc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.16, while GSK plc trades at $50.42 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while ProShares Ultra Bitcoin ETF pays none, and GSK plc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITUGSK
Sector
Leveraged / InverseHealth
52-Week High
$64.41$61.18
52-Week Low
$8.12$38.22
Market Cap
$102.60B
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bitcoin ETF

BITU trades at $9.145, down 1.98% today, with a bearish technical outlook as moving averages signal strong selling pressure. The stock has shown consistent dividend payments, with the latest being $0.02 per share. Recent news highlights concerns over its leveraged structure and volatility decay, impacting investor confidence.

The outlook remains cautious due to weak technical signals and negative sentiment. Risks include high volatility and underperformance in non-bull markets. Analyst consensus leans bearish, with limited fundamental data available to support a positive near-term view.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bitcoin ETF

BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.

Read more on BITU

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK